Safety and Pharmacokinetics of AZD7760 in Healthy Japanese Adult Participants

Phase 1, randomised, double-blind trial of AZD7760 in Staphylococcus aureus bloodstream infection (SABSI) (3 arms), sponsored by AstraZeneca. Primary endpoints: Occurrence of Adverse Events at 181 days and Occurrence of Medically-attended Adverse Events, Serious Adverse Events, and Adverse Events of Special Interest at 361 days. Started Jun 2026; status: active, not recruiting.